Targets › AAVR
1 program from 1 company in 3 trials: 2 Phase 3, 1 Phase 2; Infectious disease; next expected readout Nov 2026.
Possible role in axon guidance through interaction with RTN4R..; FUNCTION: (Microbial infection) Acts as a receptor for adeno-associated virus and is involved in adeno-associated virus infection through endocytosis system. (UniProt, Q8IZA0)
Open in Phaseline: the race on AAVR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vir Biotechnology | Tobevibart AAV receptor antagonist | AAVR | Phase 3 | Viral Hepatitis | Nov 2026 |
Viral Hepatitis (3)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.